// App-Quantinova.ai

902 : A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) delays pancreatic tumor metastasis and significantly alters the pancreatic tumor microenvironment

Researchers

Presenter

  • Maria M. Steele

Principal Investigators

  • William E. Fogler

  • John L. Magnani

  • Michael A. Hollingsworth

Medical Centers

  • University of Nebraska Medical Center, Omaha, NE

  • GlycoMimetics Inc, Rockville, MD.

Locations

  • United States

Companies

  • GlycoMimetics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • E-selectin

Drug/Treatment

  • Gemcitabine

  • GMI1359

  • CXCL12

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved